We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion)
Public health principles for reducing the spread of respiratory infections, including COVID-19, in the workplace.
Information about the risks of taking valproate medicines during pregnancy.
Find out about the long-term effects some people can have after having COVID-19.
Information regarding malaria incidents, announcements and guidance amendments from the UKHSA Advisory Committee on Malaria Prevention (ACMP).
Launched in January 2024, IRP aims to further help bring life-saving new medicines to UK patients without delay
Advice for medical professionals to follow when assessing drivers with miscellaneous conditions.
Find out about the symptoms of COVID-19, what to do if you or your child has them and when to get medical help.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
Find out if you can claim Enhanced R&D intensive support (ERIS) as a loss-making, small and medium enterprise (SME) based in Northern Ireland.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
The new presentation of Mounjaro gives four doses for once-a-week treatment over a month.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (29 January 2024) approved the medicine Rezzayo (rezafungin) to treat a fungal infection called invasive candidiasis.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
Veriton Pharma Limited is recalling a specific batch of Epistatus (midazolam) 2.5mg Oromucosal Solution (pre-filled oral syringes) due to confirmed out of specification results related to the product appearance.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).